CK0802 is an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells (T-Reg cells), which can be used intravenously and without HLA matching. On the surface of these... On the surface of these T-Reg cells, T-cell lung homing markers are expressed.
- Mechanism
- Curator reviewed · 1 reference
T-Reg cells engage with antigen-presenting cells lining the alveolar epithelium. This likely results in disarmament and dampening of the cytokine storm — seen with a study where there was a rapid decline in peripheral biomarkers and decreased blood levels of inflammatory cytokines after treatment with CK0802. It is also a possibility that these cells can calm inflammation where it is most active and act discriminately, avoiding general immunosuppression. This therapy is currently being investigated against COVID-19 acute respiratory distress syndrome (ARDS), inflammatory diseases, and autoimmune disorders.
- Also known as
- Allogeneic Umbilical Cord Blood Derived Regulatory T-Cells
- Code names
- CK0802
Resolves to
What you can answer from here — as of April 23, 2025
Which companies are running trials of CK0802, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account